logo
logo

Karolinska Development's Portfolio Company Anacardio Raises Sek 33 Million To Progress Clinical Development Of A Novel Therapy For Heart Failure

Feb 03, 2022•almost 4 years ago

Amount Raised

kr33 Million

Round Type

seed

Stockholm

Description

STOCKHOLM, SWEDEN February 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a fundraising of SEK 33 million comprised of a convertible loan. Karolinska Development participated in this important funding, which enables AnaCardio to proceed with the clinical development plans for the company’s lead asset AC01.

Company Information

Company

Ana Cardio

Location

Stockholm, Stockholm County, Sweden

About

With the new capital injection the company can complete the preparations to start a clinical phase 1b/2a-study with its lead asset AC01 in 2022. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. Karolinska Development participated in this important funding, which enables AnaCardio to proceed with the clinical development plans for the company’s lead asset AC01. AnaCardio is now well financed to complete the preparations of a clinical phase 1b/2a-study, expected to start in 2022,” says Viktor Drvota, CEO, Karolinska Development.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech